Replies to post #14405 on Momenta Pharmaceuticals, Inc. (MNTA)

[DewDiligence]

That was the first item in the MNTA news flow post in the ‘ReadMeFirst’ (#msg-116069975).

[DewDiligence]

With FDA approval, the soonest MNTA could launch 40mg Copaxone is Jan 2017, when TEVA’s 3-year Hatch-Waxman exclusivity on the 40mg dose expires (#msg-116497178).

[DewDiligence]

USPTO IPR against third 40mg-Copaxone patent will proceed:

http://finance.yahoo.com/news/mylan-confirms-u-patent-trademark-120000960.html

This patent is in addition to the two patents cited in the IPRs initiated on 8/25/15 (#msg-116493514).

The oral hearing for the IPR wrt all three patents is scheduled for 5/12/16.